随着重点转向癌症药物开发，BioNTech 2023 年第四季度收入下降至 15 亿欧元。 BioNTech Q4 2023 revenue dropped to €1.5bn as focus shifts to cancer drug development.

BioNTech 因与辉瑞合作生产 Covid-19 疫苗而闻名，该公司报告 2023 年第四季度的收入和利润下降，因为其重点转向癌症药物开发。 BioNTech, known for its Covid-19 vaccine with Pfizer, reported a drop in revenue and earnings for Q4 2023, as its focus shifts towards cancer drug development. 该公司 2023 年第四季度的收入为 15 亿欧元（相当于 16 亿美元），显着低于 2022 年的数字。 The company's revenues for Q4 2023 were €1.5bn (equivalent to $1.6bn), significantly lower than 2022's figures. 2023 年全年收入为 38 亿欧元，较 2022 年 173 亿欧元的收入大幅下降。 Full-year revenue for 2023 was €3.8bn, a sharp decline from 2022's revenue of €17.3bn. BioNTech 目前的目标是在 2026 年首次推出肿瘤学产品，并在 2030 年批准 10 个适应症。 BioNTech is now aiming for its first oncology launch in 2026 and ten indication approvals by 2030.